Using siRNA- and shRNA-mediated knockdown of the pro-invasion TFs STAT3 and SRF, we evaluated the efficacy of invasion-targeted therapy in GBM, identifying these TFs as potential drug targets for new therapeutic strategies against GBM (Fig. 6f). The gene discussed is SRF; the disease is glioblastoma.